| ENLIVEX THERAPEUTICS |
| Israel |
| Gesundheit |
| IL0011319527 / A119KH |
| 1BT (Frankfurt) / ENLV (NASDAQ) |
| FRA:1BT, ETR:1BT, 1BT:GR, NASDAQ:ENLV |
| - |
| https://www.enlivex.com/ |
|
Enlivex Therapeutics Ltd. is a biopharmaceutical company primarily focused on developing innovative treatments for life-threatening immune system disorders. The core of its research centers around its..
>Volltext.. |
| 246.94 Mio. EUR |
| 242.48 Mio. EUR |
| - |
| -12.72 Mio. EUR |
| 1071.06 Mio. EUR |
| 23.44 EUR |
| 0.56 Mio. EUR |
| 1.74 Mio. EUR |
| -9.58 Mio. EUR |
| 0.65 |
| - |
| - |
| - |
| - |
| - |
| - |
| ENLIVEX |
| 27.03.26 |
|